Gene Therapy for Bladder Cancer

BioCancell’s founding discovery, the H19 gene, is a controlling element for central malignant cell processes that plays a key role in carcinogenesis, tumor progression, drug resistance and metastasis in a spectrum of human cancers, including bladder cancer.

BC-819, BioCancell’s current focus, is a first-in-class and first-of-its-kind gene therapy that harnesses the cancer-specific mechanism of H19’s control elements into a targeted, recombinant DNA construct that encodes a lethal toxin specifically in malignant cells.

Clinical studies on BC-819 are currently focused on the treatment of early stage, superficial bladder cancer.